DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair,With death on the horizon, This will not stop me, Gods call only..........
DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 29Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contributio
n

Sunday, 6 December 2015

Dr. Liang Chen


 Dr. Liang Chen

Dr. Liang Chen received his B.S. degree in Environmental Science (minor: Economics) in 1999 at Nanjing University. He studied chemistry at Tulane University, where he received his Ph.D. degree in 2005 under the supervision of Professor Chao-Jun Li. He then became a Postdoctoral Researcher at Stanford University, and subsequently a Research Associate at LSU Dental School. Since 2008, he has been working in Bisco (Dental) Inc. as a Research Scientist and Senior Research Scientist.

Dr. Feng Zhou


  Dr. Feng Zhou

 Dr. Feng Zhou was born in 1983 in Wuhan, China. He received his B.S. degree from Wuhan University in 2006 and Ph.D. at the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences in 2011 under the supervision of Prof. Xiyan Lu. He is currently working as a postdoctoral fellow with Prof. Chao-Jun Li at the McGill University in Canada, focusing on the Cross-Dehydrogenative-Coupling (CDC) react-ions via C-H activations.

Saturday, 5 December 2015

Changming Qin



Changming Qin was born in Shandong, China, in 1982. He did his undergraduate work at Ludong University on preparation polymer nanocomposites under the guidance of Prof. Yucai Hu. He obtained his Masters degree in organic chemistry in 2008 at Wenzhou University under the supervision of Prof. Huayue Wu while working on palladium-catalyzed transformations of aryl boronic acids. After graduation, he went to the University of Hong Kong to work with Prof. Chi-Ming Che in 2008-2009, and then joined Prof. Huw Davies' group at Emory University in 2010. His current research is focused on design and synthesis of chiral dirhodium catalysts and their application in novel asymmetric carbenoid transformations.

Edward Emmett




Edward Emmett is originally from London and received his MChem from the University of Oxford in 2010. He joined Prof. Michael Willis's research group as an undergraduate student and remained to study for his DPhil in Organic Chemistry. His research focuses on the development of amine-sulfur dioxide complexes as SO2 surrogates in both catalytic and non-catalytic methodologies.

Michael Willis




 Michael Willis received his undergraduate education at Imperial College London, and his PhD from the University of Cambridge working with Prof. Steven V. Ley. After a postdoctoral stay with Prof. David A. Evans at Harvard University, as a NATO/Royal Society Research Fellow, he was appointed to a lectureship at the University of Bath in November 1997. In January 2007 he moved to the University of Oxford, where he is now a Professor of Chemistry and a Fellow of Lincoln College. His group's research interests are based on the development and application of new catalytic processes for organic synthesis.

Wednesday, 2 December 2015

Peter J. Skrdla

.
 
  • Department of Product Development
    London, United Kingdom

    ABOUT

    Pete received his Ph.D. degree in chemistry from the University of Arizona in 1999. He joined Merck (MSD) in the same year and worked there until 2014, at which time he took a position at GSK. He has extensive experience in drug development, working on/leading cross-functional teams, mentoring scientists and managing multiple projects/staff. He is interested in analytical R&D, particle engineering, physical pharmacy, nanotechnology and formulation approaches for poorly bio-available drugs.
     
    Links
https://www.linkedin.com/in/peter-j-skrdla-5b44a92
https://www.researchgate.net/profile/Peter_Skrdla/info
http://www.americanpharmaceuticalreview.com/1429-AuthorProfile/2020-Peter-J-Skrdla/
http://www.pubfacts.com/author/Peter+J+Skrdla


Peter J. Skrdla

Summary

Pete received his Ph.D. degree in chemistry from the University of Arizona in 1999. He joined Merck (MSD) in the same year and continued working there until 2014, progressing in his career from Senior Research Chemist to Principal Scientist. He has extensive experience in drug development, working on/leading cross-functional teams, mentoring other scientists and managing multiple projects/staff at the same time. He was directly involved in the commercialization of several Merck drugs, being responsible for both the technical and regulatory aspects of such.
In 2014, Pete joined GlaxoSmithKline (GSK) in the capacity of Team Leader, where he currently manages a group of scientists in the development of new pharmaceuticals (API and DP).
Pete's research interests include physical and chemical characterization, physical pharmacy, enabled formulations, nanotechnology, solid-state phase transformations, modeling, chromatography and thermal analysis (https://www.researchgate.net/profile/Peter_Skrdla/).

Education

University of Arizona

Ph.D., Chemistry
1995 – 1999

Experience

Team Leader

GSK
May 2014 – Present (1 year 8 months)Upper Providence, PA
Coordinates the activities of a group of scientists in support of the development of new medicines. Participates on cross-functional teams with the same mission.

Principal Scientist, ADC, MMD

Merck
April 2013 – March 2014 (1 year)Rahway, NJ
Technical Team Lead (TTL)

Principal Scientist, Preformulation, MRL

Merck
October 2012 – May 2013 (8 months)Summit, NJ
Preformulation scientist working on preparing and characterizing prototype formulations, enabled formulations (rotational opportunity)

Senior Investigator, MMD

Merck & Co., Inc.
January 2008 – August 2012 (4 years 8 months)Rahway, NJ
Analytical team leader, ADC

Principal Analytical Chemist, MMD

Merck
January 2007 – December 2007 (1 year)Rahway, NJ
Group leader, Analytical Development & Commercialization (ADC)

Research Fellow, MRL

Merck
August 2002 – December 2006 (4 years 5 months)Rahway, NJ
Group leader, Analytical Research (AR)

Senior Research Chemist, MRL

Merck & Co., Inc.
July 1999 – August 2002 (3 years 2 months)Rahway, NJ
Ph.D. scientist and project leader, Analytical Research (AR)

RESEARCH EXPERIENCE

  • Jul 1999–present
    Principal Investigator
    Merck · Analytical Chemistry and Development
    United States · Whitehouse Station
  • Sep 1995–Jul 1999
    Research/Teaching Assistant
    The University of Arizona · Department of Chemistry and Biochemistry (College of Science) · Saavedra and Armstrong
    United States · Tucson

AWARDS & ACHIEVEMENTS

  • Jan 2013
    Award: Merck Discovery Pharmaceutical Sciences Team Award
  • Aug 2012
    Award: Merck Technology Roadmap
  • May 2010
    Award: Merck Brinavess Launch Team
  • May 2007
    Award: Merck Emend-IV Launch Team
  • May 1997
    Scholarship: Graduate Mid-Career Fellowship



 


///////////

CPhI India, Dec2015, MUMBAI, INDIA.



 

With Dr Charlotte Wiles, CEO, CHEMTRIX BV , Cambridge, UK at CPhI India, Dec2015, MUMBAI, INDIA......At Pi-inc (Process Intensification Experts LLP) stall, hall 5 H47,


Meet her at.............. http://selectbiosciences.com/conferences/index.aspx?conf=FCINDIA16&se=india

Flow Chemistry India 2016

Date: Thursday, 21 January 2016 - Friday, 22 January 2016
Location: Mumbai



 


At Pi-inc (Process Intensification Experts LLP) stall, hall 5 H47, seen is Asif rangwala of ATR-ASAHI GLASS


 

At Pi-inc (Process Intensification Experts LLP) stall, hall 5 H47, seen is Mr Vijay Kirpalani with Charlotte wiles —